Quipt Home Medical Corp T.QIPT

Alternate Symbol(s): QIPT

Healthcare

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.

TSX:QIPT - Post by User

Quipt Home Medical Corp > Recent BNN comments - "needs more consistent profitability".

<< Previous

Bullboard Posts

Next >>

Post by besttobeon Feb 04, 2023 5:51pm

338 Views

Post# 35267163

Recent BNN comments - "needs more consistent profitability".

n WEAKNESS

Low valuation for in-home medical services company.
Does not own shares in the company, but has owned in the past.
Looking into buying shares in the future.
Management team has done great job growing company.

Healthcare

BUY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Company recently acquired (Great Elm). At $80M it is a sizeable deal, but adds $60M in revenue and $13M in EBITDA. Should be $2M in cost savings and it is accretive to cash flow. The market likes the deal. Good earnings growth is expected. Unlock Premium - Try 5i Free

Healthcare

TOP PICK

Trades at significant discount of 2 multiple points to peers. Grows organically and by acquisition. CPI increase to Medicare and Medicaid has delivered price increases. No dividend. (Analysts’ price target is $14.20)

Healthcare

Unspecified

The underlying business is doing well but the stock is way down. It has a fortified balance sheet, is growing organically`and by acquisition. They have set up a recent bank arrangement for this. It should move in line with its peers.

Healthcare

PAST TOP PICK

(A Top Pick Nov 19/21, Down 35%) Respiration industry (repository technology and machines). Business growing well. Revenue growing with profits. Trading at 50% of multiple compared to peers. Will continue to hold shares.

Healthcare

PAST TOP PICK

(A Top Pick Sep 02/21, Down 19%) It deals in home care products, e.g. oxygen, etc. It has been growing the business by 30% over the year but the stock price is down because it is a small cap company. A different market moves them substantially higher. A recent banking deal allows for more acquisitions. It is moving from a regional player to a national one. Next year a lot of catalysts could move it higher.

Healthcare

WATCH

It is a Canadian company operating in just the U.S. The CEO has done a good job growing the business. It screens cheaply but needs more consistent profitability.

Healthcare

PAST TOP PICK

(A Top Pick Sep 02/21, Down 30%) Health care is moving into homes so it is in a good spot. It is still making accretive acquisitions and guiding 30% higher revenue. It is in 19 states. He continues to hold the debentures.

Healthcare

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues have grown 41% since 2020 at $102M for 2021. 10% organic growth. Operational metrics are impressive that sets up the company well for future recurring revenues. Still some runway left, trading at 22x earnings. The balance sheet is healthy with net cash. Unlock Premium - Try 5i Free

Healthcare

TOP PICK

Home healthcare business with chronically ill patients. Growing organically at 10% per year. They are also acquiring companies and just announced 2 acquisitions. Fantastic margin at 22% EBITDA. The stock trades at 6x next year's EBITDA compared to 10x for their peers. Buying more right now. Will go higher as it gets rerated. (Analysts’ price target is $12.23)

Healthcare

TOP PICK

Chronic care, ventilators. Revenue growing at a fantastic rate, using a subscription model. Cheap compared to peers. Not a concern whether Medicare or Medicaid are cut. Perfect example of money rotation to small caps. Management owns a fairly good position. No dividend. (Analysts’ price target is $121.37)

Healthcare

PAST TOP PICK

(A Top Pick Jul 02/20, Up 72%) A US medical device company (lifts, oxyegen and other homecare products). Continues to like it, given aging demographics. The valuation is attractive. They continue to grow by acqusition, adding geographic regions and fragmented, small busineses. They have cash to buy more companies and are EBIDTA positive. Good cash flow. Expects this to get taken out one day. Price pressures are always a possibility if suppliers raise prices. Also there are reimbursement cuts in the U.S. medical system every few years, another caveat.

Healthcare

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing